XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Balance Sheet Components | 9 Months Ended
--- | ---
Sep. 30, 2022
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Components | 7. Balance Sheet Components Property and Equipment, net Property and equipment, net consists of the following:
|  | September 30, 2022 |  |  | December 31, 2021 |
|  | (in thousands) |
Laboratory equipment |  | $ | 30,022 |  |  | $ | 20,012 |
Computer equipment |  |  | 2,560 |  |  |  | 1,112 |
Furniture and fixtures |  |  | 1,911 |  |  |  | 1,443 |
Leasehold improvements |  |  | 8,780 |  |  |  | 7,834 |
Construction in progress |  |  | 75,877 |  |  |  | 26,925 |
Property and equipment, gross |  |  | 119,150 |  |  |  | 57,326 |
Less accumulated depreciation and amortization |  |  | (18,924 | ) |  |  | (14,492 | )
Total property and equipment, net |  | $ | 100,226 |  |  | $ | 42,834 |
Depreciation and amortization expenses were $1.6 million and $4.4 million for the three and nine months ended September 30, 2022, and $1.4 million and $3.9 million for the three and nine months ended September 30, 2021, respectively. Accrued and Other Liabilities Accrued and other liabilities consist of the following:
|  | September 30, 2022 |  |  | December 31, 2021 |
|  | (in thousands) |
Milestone payable |  | $ | — |  |  | $ | 95,000 |
Net profit-sharing amount |  |  | 61,684 |  |  |  | — |
Accrued income taxes |  |  | 98,189 |  |  |  | 6,217 |
Accrued royalties |  |  | 27,771 |  |  |  | 58,672 |
Research and development expenses |  |  | 40,116 |  |  |  | 28,073 |
Payroll and related expenses |  |  | 23,714 |  |  |  | 29,753 |
Other professional and consulting expenses |  |  | 5,633 |  |  |  | 2,791 |
Operating lease liabilities, current |  |  | 4,115 |  |  |  | 3,927 |
Excess funds payable under grant agreements |  |  | — |  |  |  | 1,825 |
Other accrued expenses |  |  | 21,394 |  |  |  | 10,254 |
Total accrued and other liabilities |  | $ | 282,616 |  |  | $ | 236,512 |
Accrued royalties represents royalties earned by third-party licensors, such as Xencor, on net sales of sotrovimab by GSK.

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI https://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration